Recent Analysts’ Ratings Changes for Ascendis Pharma A/S (ASND)

A number of firms have modified their ratings and price targets on shares of Ascendis Pharma A/S (NASDAQ: ASND) recently:

• 9/10/2026 – Ascendis Pharma A/S was given a new $344.00 price target by HC Wainwright.
• 9/10/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by TD Cowen.
• 9/10/2026 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/1/2026 – Ascendis Pharma A/S had its price target raised by Oppenheimer Holdings, Inc. from $304.00 to $312.00. They now have an “outperform” rating on the stock.
• 9/1/2026 – Ascendis Pharma A/S had its price target lowered by Morgan Stanley from $275.00 to $273.00. They now have an “overweight” rating on the stock.
• 9/1/2026 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by Wedbush. They now have a $327.00 price target on the stock.
• 8/31/2026 – Ascendis Pharma A/S had its price target lowered by Jefferies Financial Group Inc. from $333.00 to $330.00. They now have a “buy” rating on the stock.
• 8/31/2026 – Ascendis Pharma A/S had its price target lowered by Stifel Nicolaus from $328.00 to $326.00. They now have a “buy” rating on the stock.
• 8/31/2026 – Ascendis Pharma A/S was given a new $345.00 price target by UBS Group AG.
• 8/31/2026 – Ascendis Pharma A/S had its price target lowered by Bank of America Corporation from $306.00 to $304.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Ascendis Pharma A/S is now covered by HC Wainwright. They set a “buy” rating and a $345.00 price target on the stock.
• 8/27/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by HC Wainwright. They now have a $345.00 price target on the stock.
• 8/18/2026 – Ascendis Pharma A/S is now covered by BMO Capital Markets. They set an “outperform” rating and a $319.00 price target on the stock.
• 8/18/2026 – Ascendis Pharma A/S is now covered by BMO Capital Markets. They set an “outperform” rating and a $319.00 price target on the stock.
• 8/15/2026 – Ascendis Pharma A/S was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/14/2026 – Ascendis Pharma A/S had its price target raised by Royal Bank Of Canada from $280.00 to $290.00. They now have an “outperform” rating on the stock.
• 8/14/2026 – Ascendis Pharma A/S had its price target raised by TD Cowen from $325.00 to $341.00. They now have a “buy” rating on the stock.
• 8/14/2026 – Ascendis Pharma A/S had its price target lowered by Barclays PLC from $345.00 to $329.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $333.00 price target on the stock.
• 7/23/2026 – Ascendis Pharma A/S had its price target raised by Morgan Stanley from $256.00 to $275.00. They now have an “overweight” rating on the stock.
• 7/18/2026 – Ascendis Pharma A/S was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/15/2026 – Ascendis Pharma A/S was upgraded by Weiss Ratings from “sell (d)” to “hold (c)”.

Insider Buying and Selling

In related news, SVP Mads Bodenhoff sold 3,000 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president owned 3,000 shares in the company, valued at approximately $810,570. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jean-Jacques Bienaimé bought 2,000 shares of Ascendis Pharma A/S stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the transaction, the director owned 2,900 shares of the company’s stock, valued at $714,357. This represents a 222.22% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.